Нейтронная эмиссия в хрупких породах в ходе испытаний на сжатие. Монотонное и циклическое нагружение

Rituximab seems to be more effective and is less costly than natalizumab in the management of RRMS. Ocrelizumab does not seem to slow the rates of disease progression among patients previously treated with natalizumab.